JNJ
JOHNSON & JOHNSON
NYSE · Healthcare · Drug Manufacturers - General · US
$253.96
−0.63%Next report
Analyst consensus
- Next report date
- Jan 20, 2027
- EPS estimate
- $2.92
- Revenue estimate
- $26.4B
Latest reported
- Last report date
- Oct 13, 2026
- EPS actual
- $2.59
- EPS estimate
- $2.53
- Revenue actual
- $25.4B
- Revenue estimate
- $25.4B
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 9
- EPS misses (12Q)
- 0
- EPS in line (12Q)
- 3
- Avg surprise (4Q)
- +1.3%
- Revenue beats (12Q)
- 7
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $294
- PT range
- $272 – $320
- Analysts
- 9
8 Buy1 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Oct 13, 2026 | $2.53 | $2.59 | Beat 2.37% | $25.4B |
| Jul 15, 2026 | $2.84 | $2.90 | Beat 2.04% | $25.3B |
| Apr 14, 2026 | $2.69 | $2.70 | Beat 0.52% | $24.1B |
| Jan 21, 2026 | $2.45 | $2.46 | Beat 0.33% | $24.6B |
| Oct 14, 2025 | $2.75 | $2.80 | Beat 1.78% | $24.0B |
| Jul 16, 2025 | $2.68 | $2.77 | Beat 3.32% | $23.7B |
| Apr 15, 2025 | $2.58 | $2.77 | Beat 7.36% | $21.9B |
| Jan 22, 2025 | $2.00 | $2.04 | Beat 2.26% | $22.5B |
| Oct 15, 2024 | $2.22 | $2.42 | Beat 9.01% | $22.5B |
| Jul 17, 2024 | $2.71 | $2.82 | Beat 3.94% | $22.4B |
| Apr 16, 2024 | $2.64 | $2.71 | Beat 2.57% | $21.4B |
| Jan 23, 2024 | $2.27 | $2.29 | Beat 0.70% | $21.4B |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Jan 20, 2027